Efficacy and Safety of Tenofovir-Based Rescue Therapy for Chronic Hepatitis B Patients with Previous Nucleo(s/t)ide Treatment Failure
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Cho I. | - |
dc.contributor.author | Kwon, So Young | - |
dc.contributor.author | Kim, Jeong Han | - |
dc.contributor.author | Choe, Won Hyeok | - |
dc.contributor.author | Lee, Chang Hong | - |
dc.contributor.author | Yoon, Eileen L. | - |
dc.contributor.author | Yeon, Jong Eun | - |
dc.contributor.author | Byun, Kwan Soo | - |
dc.contributor.author | Kim, Yun Soo | - |
dc.contributor.author | Kim, Ju Hyun | - |
dc.date.accessioned | 2021-09-05T12:45:07Z | - |
dc.date.available | 2021-09-05T12:45:07Z | - |
dc.date.created | 2021-06-15 | - |
dc.date.issued | 2014-01 | - |
dc.identifier.issn | 1976-2283 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/99681 | - |
dc.description.abstract | Background/Aims: We investigated the efficacy and safety of tenofovir disoproxil fumarate (TDF)-based treatment in chronic hepatitis B (CHB) patients who failed previous antiviral therapies. Methods: Seventeen patients who failed to achieve virological responses during sequential antiviral treatments were included. The patients were treated with TDF monotherapy (four patients) or a combination of TDF and lamivudine (13 patients) for a median of 42 months. Hepatitis B virus (HBV) DNA and hepatitis B e antigen (HBeAg) were measured, and renal function was also monitored: Results: Prior to TDF therapy, 180 M, 204 I/V/S, 181 T/V, 236 T, and 184 L mutations were detected. After TDF therapy, the median HBV DNA level decreased from 4.6 log(10) IU/mL to 2.0 log(10) IU/mL and to 1.6 log(10) IU/mL at 12 and 24 months, respectively. HBV DNA became undetectable (<= 20 IU/mL) in 14.3%, 41.7%, and 100% of patients after 12, 24, and 48 months of treatment, respectively. HBeAg loss was observed in two patients. Viral breakthrough occurred in five patients who had skipped their medication. No significant changes in renal function were observed. Conclusions: TDF-based rescue treatment is effective in reducing HBV DNA levels and is safe for patients with CHB who failed prior antiviral treatments. Patients' adherence to medication is related to viral rebound. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | EDITORIAL OFFICE GUT & LIVER | - |
dc.subject | ADEFOVIR DIPIVOXIL | - |
dc.subject | DISOPROXIL FUMARATE | - |
dc.subject | ANTIVIRAL TREATMENT | - |
dc.subject | LAMIVUDINE | - |
dc.subject | VIRUS | - |
dc.subject | RESISTANCE | - |
dc.subject | MONOTHERAPY | - |
dc.subject | SUSCEPTIBILITY | - |
dc.subject | REPLICATION | - |
dc.subject | COMBINATION | - |
dc.title | Efficacy and Safety of Tenofovir-Based Rescue Therapy for Chronic Hepatitis B Patients with Previous Nucleo(s/t)ide Treatment Failure | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Yeon, Jong Eun | - |
dc.contributor.affiliatedAuthor | Byun, Kwan Soo | - |
dc.identifier.doi | 10.5009/gnl.2014.8.1.64 | - |
dc.identifier.scopusid | 2-s2.0-84893126853 | - |
dc.identifier.wosid | 000329950200010 | - |
dc.identifier.bibliographicCitation | GUT AND LIVER, v.8, no.1, pp.64 - 69 | - |
dc.relation.isPartOf | GUT AND LIVER | - |
dc.citation.title | GUT AND LIVER | - |
dc.citation.volume | 8 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 64 | - |
dc.citation.endPage | 69 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART001845662 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | ADEFOVIR DIPIVOXIL | - |
dc.subject.keywordPlus | DISOPROXIL FUMARATE | - |
dc.subject.keywordPlus | ANTIVIRAL TREATMENT | - |
dc.subject.keywordPlus | LAMIVUDINE | - |
dc.subject.keywordPlus | VIRUS | - |
dc.subject.keywordPlus | RESISTANCE | - |
dc.subject.keywordPlus | MONOTHERAPY | - |
dc.subject.keywordPlus | SUSCEPTIBILITY | - |
dc.subject.keywordPlus | REPLICATION | - |
dc.subject.keywordPlus | COMBINATION | - |
dc.subject.keywordAuthor | Antiviral agents | - |
dc.subject.keywordAuthor | Treatment outcome | - |
dc.subject.keywordAuthor | Hepatitis B | - |
dc.subject.keywordAuthor | Resistance | - |
dc.subject.keywordAuthor | Tenofovir | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.